Stem Cell Oversight Committee (SCOC)-approved human embryonic stem cell lines
The following human embryonic stem cell lines were reviewed by the Stem Cell Oversight Committee (SCOC), found to conform to the Tri-Agency Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) or, prior to December 9, 2014, the Guidelines for Human Pluripotent Stem Cell Research, and approved by CIHR’s Governing Council.
Research proposals conducted under the auspices of an institution eligible to administer Agency funds and that use these cell lines need to be reviewed and approved by SCOC, and their institutional Research Ethics Board before the work can commence.
Cell Line | Source |
---|---|
CA1, CA2 | Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital |
CC1, CC3 | University of Calgary |
CyT49 | CyThera, Inc. |
Elf1 (limited to non-commercial uses) | WiCell |
ES2, ES3, ES4, ES5, ES6 | Centre for Regenerative Medicine of Barcelona |
ESI-017, ESI-035, ESI-049, ESI-051, ESI-053 | ESI BIO |
H1, H7, H9, H14 | WiCell |
HAD-C 102, HAD-C 104, HAD-C 106 | Hadassah Human Embryonic Stem Cell Research Center |
hES1, hES2, hES3, hES4, hES5, hES6 | ESI BIO |
HSF-6 | University of California, San Francisco |
HUES 1-28, 64 | HSCI iPS Core, Harvard University |
I3, I6 | Technion-Israel Institute of Technology |
KCL-003-CF1 | King's College |
MEL1, MEL2 | Millipore Corporation |
RUES1-3 | The Rockefeller University |
VUB01, VUB02, VUB03_DM1, VUB04_CF, VUB05_HD, VUB06, VUB08_MFS, VUB09_FSHD, VUB10_SCA, VUB11_FXS, VUB12_FXS, VUB13_DM1, VUB14, VUB19_DM1, VUB20_CMT1A, VUB22_CF, VUB23_OI, VUB24_DM1, and VUB28_HD_MFS (each limited to non-commercial uses) | Vrije Universiteit Brussel |
WIBR1, WIBR2, WIBR3 | Whitehead Institute |
UCLA 1-18, UCLA 19n, UCLA 20n | University of California, Los Angeles |
- Date modified: